The market for pharmaceuticals to treat chronic heart failure could climb to nearly $9 billion over the next decade, one market research report estimated.

Decision Resources Group calculated that the market will grow from $2.9 billion in 2013 to $8.9 billion in 2023, based the prevalence of the disease and market trends. The report highlighted the pent-up demand for new therapies to treat symptoms, improve survival and reduce costly rehospitalizations.

“Pharmacological therapy for AHF [acute heart failure] has been unchanged for decades,” according to the report. “No treatment has yet been shown, convincingly, to reduce morbidity and mortality in CHF [chronic heart failure] patients with preserved ejection fraction. Recent efforts to develop new therapies for AHF and CHF have been largely unsuccessful.”

The analysis covers seven markets—the U.S., France, Germany, Italy, Spain, United Kingdom, Japan—and is based on a patient-based model. The projections include novel biologic vasodilators and other new agents that could be commercially available in coming years. These options nonetheless will face competition from less-expensive and familiar generics, the authors cautioned.